New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 18, 2019, Pfizer announced the FDA approval of Abrilada (adalimumab-afzb), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
